Literature DB >> 6124064

Interaction of ranitidine with liver microsomes.

S Rendić, T Alebić-Kolbah, F Kajfez, H H Ruf.   

Abstract

1. Ranitidine interacts with liver microsomes from rats pretreated with different inducers of cytochrome P-450 to produce substrate difference optical spectra with a peak at 426-429 nm and a trough at 390-400 nm. 2. Cytochrome P-450 reduced with dithionite in the presence of ranitidine produced substrate difference spectra with a peak at 447 nm. 3. Ks values for the interaction of ranitidine with cytochrome P-450 (not reduced), calculated from double reciprocal plots, were in the range 1.4-2.8 mM. 4. The O-dealkylation of 7-ethoxycoumarin and of p-nitroanisole was inhibited by the presence of ranitidine and the inhibition was of a mixed type. Kii and Kis values were: for inhibition of 7-ethoxycoumarin dealkylation, 0.8 to 9 mM, and 0.16 to 0.67 mM, respectively; for inhibition of p-nitroanisole dealkylation, 5.8 to 13.7 mM, and 1 to 4.5 mM, respectively. 5. The I50 values for 7-ethoxycoumarin dealkylation was 1.8 mM and for p-nitroanisole dealkylation about 7.2 mM (microsomes from phenobarbital-pretreated rats). 6. The e.p.r. spectra of cytochrome P-450 from phenobarbital-pretreated rats, in the presence of ranitidine, reveal two types of interaction depending on the ranitidine concentration. At lower concentrations of ranitidine, a ligand exchange reaction with an oxygen atom is indicated, and at higher concentrations are with nitrogenous or thioether ligand of ranitidine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124064     DOI: 10.3109/00498258209052450

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  21 in total

1.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 2.  Haematological adverse effects of histamine H2-receptor antagonists.

Authors:  J P Aymard; B Aymard; P Netter; B Bannwarth; P Trechot; F Streiff
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

3.  A dog model for acetaminophen-induced fulminant hepatic failure.

Authors:  A Francavilla; L Makowka; L Polimeno; M Barone; J Demetris; J Prelich; D H Van Thiel; T E Starzl
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

4.  Accumulation of caffeine in healthy volunteers treated with furafylline.

Authors:  E Tarrus; J Cami; D J Roberts; R G Spickett; E Celdran; J Segura
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

5.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Influence of ranitidine on plasma metoprolol concentrations.

Authors:  D Jack; M Mitchard; R N Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

7.  Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics.

Authors:  L K Webster; G W Mihaly; D B Jones; R A Smallwood; J A Phillips; F J Vajda
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

9.  Single blind comparative study of ranitidine and cimetidine in patients with gastric ulcer. The Belgian Peptic Ulcer Study Group.

Authors: 
Journal:  Gut       Date:  1984-09       Impact factor: 23.059

10.  Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans.

Authors:  R Bendayan; J T Sullivan; C Shaw; R C Frecker; E M Sellers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.